Company Quick10K Filing
Guardion Health Sciences
10-Q 2020-03-31 Filed 2020-05-14
10-K 2019-12-31 Filed 2020-03-30
S-1 2019-10-25 Public Filing
10-Q 2019-09-30 Filed 2019-11-13
S-1 2019-08-07 Public Filing
S-1 2019-07-03 Public Filing
10-Q 2019-06-30 Filed 2019-08-12
10-Q 2019-03-31 Filed 2019-05-10
10-K 2018-12-31 Filed 2019-02-14
8-K 2020-05-14 Earnings, Exhibits
8-K 2020-04-21 Regulation FD, Other Events, Exhibits
8-K 2020-04-01 Other Events, Exhibits
8-K 2020-03-30 Earnings, Exhibits
8-K 2020-03-19 Other Events, Exhibits
8-K 2020-03-06 Other Events, Exhibits
8-K 2019-12-05 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-10-28 Enter Agreement, Other Events, Exhibits
8-K 2019-10-22 Amend Bylaw, Exhibits
8-K 2019-09-20
8-K 2019-09-20 Enter Agreement, Other Events, Exhibits
8-K 2019-08-13 Enter Agreement, Other Events, Exhibits
8-K 2019-08-12 Earnings, Exhibits
8-K 2019-07-12 Other Events
8-K 2019-04-05 Other Events, Exhibits
8-K 2019-03-15 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2019-01-30 Amend Bylaw, Exhibits
8-K 2019-01-15 Other Events

Guardion Health Sciences Financials

GHSI Metrics, Comps, Filings

Quarterly | Annual

Business

The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z® that replenishes and restores the macular protective pigment. A depleted macular protective pigment is a modifiable risk factor for retina-based diseases such as age-related macular degeneration (“AMD”), computer vision syndrome (“CVS”) and diabetic retinopathy. The Company believes this risk may be modified by taking Lumega-Z to maintain a healthy macular protective pigment. Additional research has also shown a depleted macular protective pigment to be a biomarker for neurodegenerative diseases such as Alzheimer's disease and dementia.

In September 2017, the Company, through its wholly-owned subsidiary VectorVision Ocular Health, Inc., acquired substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. VectorVision's standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. The acquisition expands the Company's technical portfolio. The Company believes the acquisition of VectorVision, adding the CSV-1000 and ESV-3000 to its product portfolio, further establishes its position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The Company has had limited commercial operations to date. Until recently with the acquisition of VectorVision and development of the Company's sales force, the Company has primarily been engaged in research, development, commercialization, and capital raising.

The Company invented a proprietary technology, embodied in the Company's medical device, the MapcatSF,® that accurately measures the macular pigment optical density (“MPOD”). On November 8, 2016, the United States Patent and Trademark Office (“USPTO”) issued patent number 9,486,136 for the MapcatSF invention. Using the MapcatSF to measure the MPOD allows one to monitor the increase in the density of the macular protective pigment after taking Lumega-Z. The MapcatSF is a non-mydriatic, non-invasive device that accurately measures the MPOD, the lens optical density and lens equivalent age, thereby creating an evidence-based protocol that is shared with the patient. A non-mydriatic device is one that does not require dilation of the pupil for it to function. The MapcatSF is the first medical device using a patented “single fixation” process and “automatic lens density correction” that produces accurate serialized data.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Parallax Health Sciences (PRLX) 41,922 280% -5.4 -333% 2,373 7,209 82 229 -7,914 -7,871 42,507
Sanuwave Health (SNWV) 41,781 42% -5.8 -467% 1,644 14,962 693 290 -7,680 -7,149 41,378
ATI Nationwide Holding (ATIN) 41,622 -862.6 -3,752% 1 19 0 0 -48 -48 41,621
India Globalization Capital (IGC) 40,759 2% -5.1 -16% 32,887 1,645 6,297 141 -5,284 -5,207 26,696
Portsmouth Square (PRSI) 40,747 24% 13.7 4% 62,481 135,874 59,500 14,496 2,290 12,407 169,553
Medovex (MDVX) 40,687 75% -3.7 -66% 17,580 8,020 6,498 4,897 -11,616 -10,904 40,342
MJ Holdings (MJNE) 40,433 31% -12.8 -27% 11,993 5,152 779 240 -3,278 -3,125 39,929
Barfresh (BRFH) 40,406 56% -16.8 -60% 6,592 4,566 3,782 2,137 -3,950 -2,523 42,352
EPHS Holdings (STNN) 40,182 -65.5 -21% 3,196 2,664 0 0 -658 -638 41,794
Pharmacyte Biotech (PMCB) 39,956 -9.9 -75% 5,338 804 0 0 -4,016 -4,016 39,911
Guardion Health Sciences (GHSI) 39,881 61% -5.4 -76% 8,955 906 665 403 -6,819 -6,353 34,326
Super League Gaming (SLGG) 39,507 54% -1.1 -138% 18,773 1,567 822 443 -25,991 -25,147 26,921
Smith Midland (SMID) 39,433 20% 13.6 3% 40,403 20,126 34,250 6,971 1,178 2,992 40,678
Earth Science Tech (ETST) 39,246 53% -19.3 -600% 352 833 597 316 -2,113 -2,030 39,211
Xspand Products Lab (XSPL) 38,927 30% -18.2 -24% 9,639 4,622 7,819 2,365 -2,304 -2,080 37,914
First Choice Healthcare Solutions (FCHS) 38,514 16.2 3% 27,801 7,984 0 0 832 1,917 31,130
Echelon (ELON) 38,425 55% -8.2 -17% 28,010 6,437 31,601 17,474 -4,655 -4,090 33,505
AIT Therapeutics (AITB) 38,356 -2.1 -310% 5,265 10,272 0 0 -16,345 -16,330 33,491
Protagenic (PTIX) 38,275 -42.3 -313% 287 651 0 0 -899 -899 37,998
Williams Industrial Services Group (WLMS) 38,114 12% 31.0 2% 105,953 84,820 223,335 27,162 1,988 2,354 72,978

Balance Sheet ($'000)2016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash634452981,2704,7353,1982,0661,1026711742,3695,555
Accounts Receivable222547357301728153622
Inventory4450108178155183412381358304319320
PP&E277277283312324419461552584589643747
Assets2626435133,8787,3705,9164,8653,8863,6813,9715,6988,955
Accounts Payable
Long-Term Debt
Liabilities6084902567565006005873994952,0831,010906
Stockholders' Equity3461542563,1226,8705,3164,2783,4873,1861,8884,6888,049
Income Statement ($'000)2016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue566063259193221294243261161
Cost of Revenue2330309379137125939771
Gross Profit33303316611413316914916490
R&D1016106128160895297832
SG&A6768681,5092,2312,2871,7011,3051,3022,8982,471
Tax00000000
Net Income-669-856-1,584-2,196-2,333-1,810-2,148-1,385-3,048-2,385
Cash Flow ($'000)2016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-446-578-1,489-1,354-1,071-864-586-1,908-1,695
Cash Investing0-6-12-145-42-91-5-54-104
Cash Financing8284364,967-38-19-9944,1564,986